Major Pharmaceuticals Scaling ADC Platforms
Large pharmaceutical companies have utilized strategic acquisitions to access validated ADC Platforms. Daiichi Sankyo continues to maintain a dominant leadership position built upon its proprietary DXd platform technology. This highly successful system utilizes a topoisomerase I inhibitor payload connected via a stable, tumor-selective cleavable linker.
Emerging Biotech Companies Redefining ADC Platforms
Beyond the mega-cap players, highly specialized biotechs are pioneering the next evolution of ADC Platforms:
| Company | Platform Technology | Mechanism & Clinical Benefit |
|---|---|---|
| Alphamab Oncology | Glycan-Specific Conjugation | Uses a “one-enzyme, two-step” approach to attach dual payloads, maximizing efficacy against heterogeneous tumors. |
| Sutro Biopharma | Cell-Free Protein Synthesis | Incorporates non-natural amino acids for precise, site-specific bioconjugation of immunostimulatory payloads. |
| Orum Therapeutics | TPD² (Targeted Protein Degradation) | Combines targeted protein degradation with antibody delivery to eliminate undruggable intracellular targets. |
The Future of Specialized ADC Platforms
The utilization of conditionally active biologics is another breakthrough driven by novel ADC Platforms. As these proprietary systems mature, they promise to vastly expand the range of targetable antigens while protecting healthy tissues from severe toxicities.
References
- Daiichi Sankyo. DXd ADC Technology Platform Specifications.
- Alphamab Oncology (HKEX: 9966). Voluntary Announcement on JSKN027 Glycan-Specific Technology.